SKLB-287, A novel oral multikinase inhibitor of EGFR and VEGFR2, Exhibits potent antitumor activity in LoVo colorectal tumor model

Neoplasma

Volumn 61, Issue 5, 2014, Pages 514-522

  Chen, X ^a   Liu, Y ^b   Yang, H W ^a   Zhou, S ^a   Cheng, C ^a   Zheng, M W ^a   Zhong, L ^a   Fu, X Y ^c   Pan, Y L ^a   Ma, S ^a   Tang, Y ^c   Chen, Y Z ^a   Li, L L ^c   Yang, S Y ^a  

^a SICHUAN UNIVERSITY   (China)

^b 452nd Hospital of People's Liberation Army   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Colorectal cancer; EGFR; SKLB 287

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; SKLB 287; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE INHIBITOR; SKLB-287; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ASSESSMENT; COLORECTAL TUMOR; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MTT ASSAY; NICK END LABELING; NONHUMAN; PHARMACODYNAMICS; TRANSGENIC ZEBRAFISH; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; PATHOLOGY; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MICE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84907287301     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_063     Document Type: Article

References (38)

1. Shaw P, Costa J. Molecular biology of colon cancer (review). Anticancer Res 1989; 9: 21–27.
2. SOCIETY AC CANCER FACTS & FIGURES 2012. Atlanta: American Cancer Society 2012.
3. Saif MW. Targeted agents for adjuvant therapy of colon cancer. Clin Colorectal Cancer 2006; 6: 46–51. http://dx.doi.org/10.3816/CCC.2006.n.020
4. EL Zouhairi M, Charabaty A, Pishvaian MJ. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res 2011; 4: 15–21.
5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341–354. http://dx.doi.org/10.1038/nrc1609
6. Krasinskas AM. EGFR Signaling in Colorectal Carcinoma. Patholog Res Int 2011; 2011: 932932.
7. VAN Schaeybroeck S, Karaiskou-Mccaul A, Kelly D, Longley D, Galligan L, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005; 11: 7480–7489. http://dx.doi.org/10.1158/1078-0432.CCR-05-0328
8. Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, et al. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005; 16: 189–194. http://dx.doi.org/10.1093/annonc/mdi057
9. Mckay JA, Murray LJ, Curran S, Ross VG, Clark C, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002; 38: 2258–2264. http://dx.doi.org/10.1016/S0959-8049(02)00234-4
10. Jimeno A, Gravalos C, Escudero P, Sevilla I, Vega-Villegas ME, et al. Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. Clin Transl Oncol 2008; 10: 52–57. http://dx.doi.org/10.1007/s12094-008-0153-5
11. Perez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 2004; 10: 4238s–4240s. http://dx.doi.org/10.1158/1078-0432.CCR-040017
12. Trarbach T, Reinacher-Schick A, Hegewischbecker S, Vanhoefer U, Frieling T, et al. Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Onkologie 2010; 33: 89–93. http://dx.doi.org/10.1159/000277635
13. Hartmann JT, Pintoffl JP, Kroning H, Bokemeyer C, Holtmann M, et al. Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). Onkologie 2008; 31: 237–241. http://dx.doi.org/10.1159/000122029
14. Sharma SP. Cetuximab for metastatic colorectal cancer. Lancet Oncol 2007; 8: 673. http://dx.doi.org/10.1016/S1470-2045(07)70224-3
15. Jonker DJ, O‘Callaghan CJ, Karapetis CS, Zalcberg JR, TU D, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040–2048. http://dx.doi.org/10.1056/NEJMoa071834
16. Chen MC, Chiang FF, Wang HM. Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: Effect of KRAS mutation on treatment efficacy in Taiwanese patients. Neoplasma 2013; 60: 561–567. http://dx.doi.org/10.4149/neo_2013_073
17. Goldberg RM, Venook AP, Schilsky RL. Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol 2004; 2: 1–10; quiz 11–12.
18. Elez E, Alsina M, Tabernero J. Panitumumab – an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status. Cancer Treat Rev 2010; 36 Suppl 1: S15–16. http://dx.doi.org/10.1016/S0305-7372(10)70003-7
19. Wisinski KB, Mulcahy MF, Benson AB 3rd. Panitumumab in metastatic colorectal cancer. Clin Adv Hematol Oncol 2007; 5: 10–11.
20. Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba- Rodriguez R, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptorexpressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecancontaining chemotherapy regimens. Clin Cancer Res 2008; 14: 1296–1302. http://dx.doi.org/10.1158/1078-0432.CCR-07-1354
21. Mano M, Humblet Y. Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat Clin Pract Oncol 2008; 5: 415–425. http://dx.doi.org/10.1038/ncponc1136
22. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563–572. http://dx.doi.org/10.1056/NEJMoa0808268
23. Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol 2012; 5: 63. http://dx.doi.org/10.1186/1756-8722-5-63
24. Thairu N, Kiriakidis S, Dawson P, Paleolog E Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis 2011; 14: 223–234. http://dx.doi.org/10.1007/s10456-011-9208-2
25. Mulder K, Scarfe A, Chua N, Spratlin J. The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opin Biol Ther 2011; 11: 405–413. http://dx.doi.org/10.1517/14712598.2011.557657
26. Usakova V, Sevcikova K, Usak J, Bartosova Z, Mikulova M, et al. Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma. Neoplasma 2013; 60: 83–91. http://dx.doi.org/10.4149/neo_2013_012
27. Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, et al. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study. Cancer 2013.
28. Yang J, Wang LJ, Liu JJ, Zhong L, Zheng RL, et al. Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9Hpurine- 2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. J Med Chem 2012; 55: 10685–10699. http://dx.doi.org/10.1021/jm301365e
29. Pan Y, Xu Y, Feng S, Luo S, Zheng R, et al. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo. Mol Cancer Ther 2012; 11: 952–962. http://dx.doi.org/10.1158/1535-7163.MCT-11-0679
30. Heo DS, Park JG, Hata K, Day RM, Herberman RB, et al. Evaluation of Tetrazolium-based Semiautomatic Colorimetric Assay for Measurement of Human Antitumor Cytotoxicity. Cancer Res 1990; 50: 3681–3690.
31. Cao ZX, Liu JJ, Zheng RL, Yang J, Zhong L, et al. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3- driven AML and considerable potency in models of CML harboring Abl mutants. Leukemia 2012; 26: 1892–1895. http://dx.doi.org/10.1038/leu.2012.67
32. Zhang S, Cao ZX, Tian HW, Shen GB, MA YP, et al. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res 2011; 17: 4439–4450. http://dx.doi.org/10.1158/1078-0432.CCR-10-3109
33. Zhou JP, Chen X, Feng S, Luo SD, Pan YL, et al. Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers. PLoS One 2011; 6: e28930. http://dx.doi.org/10.1371/journal.pone.0028930
34. Apati A, Janossy J, Brozik A, Bauer PI, Magocsi M Calcium induces cell survival and proliferation through the activation of the MAPK pathway in a human hormonedependent leukemia cell line, TF-1. J Biol Chem 2003; 278: 9235–9243. http://dx.doi.org/10.1074/jbc.M205528200
35. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001; 85: 584–589. http://dx.doi.org/10.1054/bjoc.2001.1936
36. Tonra JR, Deevi DS, Corcoran E, LI H, WANG S, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor- 2 targeted therapy. Clin Cancer Res 2006; 12: 2197–2207. http://dx.doi.org/10.1158/1078-0432.CCR-05-1682
37. Brown DC, Cole D, Gatter KC, Mason DY Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki67. Br J Cancer 1988; 57: 178–181. http://dx.doi.org/10.1038/bjc.1988.37
38. Parast CV, Mroczkowski B, Pinko C, Misialek S, Khambatta G, et al. Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry 1998; 37: 16788–16801. http://dx.doi.org/10.1021/bi981291f